surmount-1 tirzepatide non-diabetic obesity trial 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers SURMOUNT-1 Study Finds Individuals with

Doing so provides timely, essential feedback about what youre doing, how well its working, and whether a stall is a blip on the radar or a real plateau

Tirzepatide is approved for adults with type 2 diabetes

The most common issues are nausea, vomiting, diarrhea, and constipation

While we wont list specific alternatives in this section, its important to know that many other treatments have been studied more extensively in pregnant women and may be safer to use

Clinical studies have shown that patients may achieve 1520% total body weight loss, making it an effective prescription weight loss treatment when prescribed and monitored under doctor supervision